Altered microRNA Profiles and Associated Pathways in Canine Mammary Adenocarcinoma
Canine mammary tumors remain one of the most common neoplastic diagnoses in intact female dogs, and they continue to challenge clinicians with their biological diversity and unpredictable behavior. Among these tumors, mammary gland adenocarcinoma stands out for its aggressive nature and clinical relevance. Beyond their impact on canine health, these tumors also offer a powerful comparative model for human breast cancer. A recent study exploring microRNA expression in canine mammary adenocarcinoma adds a fresh molecular layer to this conversation and it is surprisingly relatable to what we already know from human oncology.
MicroRNAs, or miRNAs, are short non coding RNA molecules that fine tune gene expression. Think of them as molecular dimmer switches rather than on off buttons. When they malfunction, entire signaling pathways can tilt toward uncontrolled growth, invasion, and metastasis. In this study, researchers analyzed the expression of 84 miRNAs in canine mammary adenocarcinoma tissue and compared them to healthy mammary tissue using quantitative RT PCR. The results offer a snapshot of how small molecules can drive big biological consequences.
Several miRNAs were significantly upregulated in tumor tissue, including miR 101, miR 106b, miR 143, miR 15a, miR 205, and miR 93. Many of these have already been implicated in human breast cancer, where they are known to influence cell cycle progression, apoptosis, and tumor invasiveness. Their increased expression in canine tumors strengthens the argument that similar oncogenic mechanisms are at play across species.
On the flip side, a set of miRNAs showed notable downregulation in canine mammary adenocarcinoma. These included let 7c, miR 10b, miR 191, and miR 26a. Several of these are widely regarded as tumor suppressor miRNAs in human oncology. Reduced expression can remove important brakes on cell proliferation and differentiation, allowing malignant cells to gain momentum.
Pathway enrichment analysis tied these altered miRNA profiles to some of the most familiar signaling networks in cancer biology. The PI3K AKT mTOR pathway emerged as a major player, which is no surprise to anyone who has followed advances in targeted cancer therapies. This pathway is central to cell survival, metabolism, and growth, and its dysregulation is a hallmark of many aggressive tumors. Wnt beta catenin signaling also featured prominently, reinforcing its role in tumor initiation and progression. Additionally, miRNAs linked to epithelial to mesenchymal transition were identified, providing molecular context for invasion and metastasis in canine mammary cancer.
What makes these findings especially compelling for veterinary professionals is their translational potential. The conservation of these miRNA driven pathways between dogs and humans supports the role of canine mammary tumors as a comparative oncology model. At the same time, it opens the door for practical clinical applications in veterinary medicine. MiRNA based biomarkers could eventually help refine diagnosis, predict prognosis, or even guide treatment decisions. While we are not yet at the point of ordering miRNA panels alongside routine histopathology, the trajectory is clear.
For millennial veterinarians who trained in an era where molecular diagnostics were just entering the curriculum, studies like this bridge the gap between bench science and exam room reality. They remind us that oncology is moving fast, and that even the smallest molecules can reshape how we understand and manage cancer in our patients.
As research continues to map these molecular signatures, microRNAs may become less of a buzzword and more of a clinical tool. For canine mammary adenocarcinoma, that shift cannot come soon enough.
To read the original article: Click Here
